Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

Autor: Adam Finn, Zsuzsa Szasz-Benczur, Kazminder Fox, Maria Garcia Gonzalez, Zsolt Friedrich, Catherine Hyams, Robin Marlow, Anabella Tuner, Zandile Maseko, Robyn Heath, Leigh Morrison, Lana Ward, Gabriella Ruffino, Jennifer Oliver, David Adegbite, Rupert Antico, Jade King, Leon Danon

Publikováno v: The Lancet. Infectious Diseases
Hyams, C, Marlow, R D, Maseko, Z, King, J N, Ward, L, Fox, K, Heath, R, Turner, A, Friedrich, Z, Morrison, L, Ruffino, G, Antico, R S, Adegbite, D S, Szasz-Benczur, Z, Garcia Gonzalez, M, Oliver, J L, Danon, L & Finn, A H R 2021, ' Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years : a test-negative, case-control study ', The Lancet Infectious Diseases, vol. 21, no. 11, pp. 1539-1548 . https://doi.org/10.1016/S1473-3099(21)00330-3

Background:On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine ChAdOx1 nCoV-19 on Jan 4, 2021. Care home residents and staff, frontline health-ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5965460f19819e38e2e16b2311833b89
https://pubmed.ncbi.nlm.nih.gov/34237259